We are live on ! Find out more
CARM

Carisma Therapeutics
CARM

Delisted

CARM was delisted on the 10th of October, 2025.

Back to rankings

3 hedge funds and large institutions have $47.9K invested in Carisma Therapeutics in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

3.75% less ownership

Funds ownership: 3.75% → 0% (-3.7%)

28% less capital invested

Capital invested by funds: $67K → $47.9K (-$19.1K)

57% less funds holding

Funds holding: 7 → 3 (-4)

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
3
Holders Change
-4
Holders Change %
-57.14%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
GSEP
Golden State Equity Partners
California
+$6

Top Sellers

1
XT
XTX Topco
Cayman Islands
-$1.72K
2
EF
Empowered Funds
Pennsylvania
-$1.33K
3
BBA
Baader Bank Aktiengesellschaft
Germany
-$517
4
IA
IFP Advisors
Florida
-$9
Name Holding Trade Value Shares
Change 		Change in
Stake
MC
1
Merck & Co
New Jersey
$47.9K – – –
UBP
2
Union Bancaire Privee
Switzerland
$22 – – –
GSEP
3
Golden State Equity Partners
California
$6 +$6 +200 New
XT
4
XTX Topco
Cayman Islands
– -$1.72K -40,097 Closed
EF
5
Empowered Funds
Pennsylvania
– -$1.33K -30,988 Closed
BBA
6
Baader Bank Aktiengesellschaft
Germany
– -$517 -19,515 Closed
IA
7
IFP Advisors
Florida
– -$9 -206 Closed

CARM Hedge Fund Activity: Q1 2026 in Review

3 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q1 2026, worth a combined $47.9K — down 28% from $67K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of CARM and 1 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Golden State Equity Partners, opening a new position worth an estimated $6. The largest seller was XTX Topco, exiting entirely with an estimated $1.72K sold.

  • 3 institutional investors held Carisma Therapeutics (CARM) as of Q1 2026, down from 7 in Q4 2025.
  • Funds reported $47.9K of Carisma Therapeutics stock for Q1 2026, down 28% quarter-over-quarter.
  • 1 fund opened new Carisma Therapeutics positions in Q1 2026 and 4 closed out, a net change of -3 holders.
  • The largest Carisma Therapeutics buyer in Q1 2026 was Golden State Equity Partners, an estimated $6 added.
  • The largest Carisma Therapeutics seller in Q1 2026 was XTX Topco, an estimated $1.72K sold.

Based on aggregated 13F filings for Q1 2026.